AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer

AstraZeneca touted positive data for its Lynparza-Imfinzi blockbuster combo today with a high-level analysis from its DUO-O Phase III trial, in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutations.